Currently out of the existing stock ratings of Alex Schwartz, 13 are a BUY (86.67%), 2 are a HOLD (13.33%).

Alex Schwartz

Work Performance Price Targets & Ratings Chart

Analyst Alex Schwartz, carries an average stock price target met ratio of 25% that have a potential upside of 3.63% achieved within 11 days. Previously, Alex Schwartz worked at STIFEL.

Alex Schwartz’s has documented 26 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ANAB, AnaptysBio at 20-Feb-2024.

Wall Street Analyst Alex Schwartz

Analyst best performing recommendations are on MNTA (MOMENTA PHARMACEUTICALS).
The best stock recommendation documented was for MNTA (MOMENTA PHARMACEUTICALS) at 1/5/2018. The price target of $15 was fulfilled within 4 days with a profit of $2.55 (14.53%) receiving and performance score of 36.32.

Average potential price target upside

ESPR Esperion Therapeutics PBYI Puma Biotechnology MNTA Momenta Pharmaceuticals ANAB AnaptysBio

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$16

$14.91 (1367.89%)

$16

17 days ago
(25-Apr-2025)

0/5 (0%)

$15.08 (1639.13%)

Buy

$5

$3.91 (358.72%)

$5

17 days ago
(25-Apr-2025)

0/12 (0%)

$4.08 (443.48%)

Buy

$4

$2.91 (266.97%)

2 months 7 days ago
(05-Mar-2025)

1/12 (8.33%)

$2.35 (142.42%)

255

Buy

$4

$2.91 (266.97%)

$7

3 months 1 days ago
(11-Feb-2025)

0/3 (0%)

$2.21 (123.46%)

Hold

$4

$2.91 (266.97%)

$3.5

4 months 24 days ago
(18-Dec-2024)

8/9 (88.89%)

$1.84 (85.19%)

79

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Alex Schwartz?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?